EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3078-3086

  Guo, Shuangping ^a,f   Chan, John K C ^b   Iqbal, Javeed ^f   McKeithan, Timothy ^f   Fu, Kai ^f   Meng, Bin ^c   Pan, Yi ^d   Cheuk, Wah ^b   Luo, Donglan ^e   Wang, Ruian ^a   Zhang, Weiwei ^f   Greiner, Timothy C ^f   Chan, Wing C ^f  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN BIK; PROTEIN FOXP1; PROTEIN RASSF6P; PROTEIN TCF4; PROTEIN TCL1A; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CHINESE; CODON; CONTROLLED STUDY; ETHNIC DIFFERENCE; EZH2 GENE; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VERY ELDERLY; ENZYME IMMUNOASSAY; ETHNIC GROUP; ETHNOLOGY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GERMINAL CENTER; MIDDLE AGED; MUTATION; NONHODGKIN LYMPHOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; POLYCOMB REPRESSIVE COMPLEX 2; POLYMERASE CHAIN REACTION; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902653761     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1597     Document Type: Article

References (20)

1. Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012;120:4795-801.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-20. (Pubitemid 28394156)
3. Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int 2008;58:174-82. (Pubitemid 351190172)
4. Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol 2012;47:92-104.
5. Pan Y, Meng B, Sun B, Guan B, Liang Y, Wang H, et al. Frequencies of BCL2 and BCL6 translocations in representative chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses. Diagn Mol Pathol 2012;21:234-40.
6. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2010;117:2451-9.
7. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLOS ONE 2011;6:e28585.
8. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. PNAS 2010;107:20980-85.
9. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
10. Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011;25:726-29.
11. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
12. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
13. Dybkaer K, Iqbal J, Zhou G, Geng H, Xiao L, Schmitz A, et al. Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics 2007;8:230.
14. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010;116:5247-55.
15. Care MA, Barrans S, Worrillow L, Jack A, Westhead DR, Tooze RM. A Microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma. PLOS ONE 2013;8:e55895.
16. Aggarwal M, Villuendas R, Gomez G, Rodriguez-Pinilla SM, Sanchez-Beato M, Alvarez D, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Modern Pathol 2009;22:206-15.
17. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, et al. Tcl1 protein functions as an inhibitor of de nove DNA methylation in B-cell chronic lymphocytic leukemia (CLL). PNAS 2012;109:2555-60.
18. Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L, et al. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory diseaswith therapeutic implications. Leuk lymphoma 2012;53:1709-13.
19. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009;8:42.
20. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, et al. Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood 2012;119:6278-87.